收费全文 | 26674篇 |
免费 | 2029篇 |
国内免费 | 76篇 |
耳鼻咽喉 | 184篇 |
儿科学 | 691篇 |
妇产科学 | 686篇 |
基础医学 | 4353篇 |
口腔科学 | 378篇 |
临床医学 | 2700篇 |
内科学 | 5842篇 |
皮肤病学 | 456篇 |
神经病学 | 2268篇 |
特种医学 | 848篇 |
外国民族医学 | 5篇 |
外科学 | 3834篇 |
综合类 | 256篇 |
一般理论 | 27篇 |
预防医学 | 1991篇 |
眼科学 | 445篇 |
药学 | 1616篇 |
中国医学 | 21篇 |
肿瘤学 | 2178篇 |
2022年 | 171篇 |
2021年 | 419篇 |
2020年 | 258篇 |
2019年 | 452篇 |
2018年 | 522篇 |
2017年 | 327篇 |
2016年 | 368篇 |
2015年 | 494篇 |
2014年 | 673篇 |
2013年 | 990篇 |
2012年 | 1459篇 |
2011年 | 1533篇 |
2010年 | 855篇 |
2009年 | 798篇 |
2008年 | 1447篇 |
2007年 | 1481篇 |
2006年 | 1479篇 |
2005年 | 1376篇 |
2004年 | 1335篇 |
2003年 | 1284篇 |
2002年 | 1259篇 |
2001年 | 641篇 |
2000年 | 676篇 |
1999年 | 562篇 |
1998年 | 333篇 |
1997年 | 252篇 |
1996年 | 243篇 |
1995年 | 207篇 |
1994年 | 196篇 |
1993年 | 168篇 |
1992年 | 422篇 |
1991年 | 385篇 |
1990年 | 401篇 |
1989年 | 360篇 |
1988年 | 357篇 |
1987年 | 350篇 |
1986年 | 350篇 |
1985年 | 315篇 |
1984年 | 261篇 |
1983年 | 217篇 |
1982年 | 159篇 |
1981年 | 163篇 |
1980年 | 169篇 |
1979年 | 201篇 |
1978年 | 194篇 |
1977年 | 158篇 |
1975年 | 177篇 |
1974年 | 208篇 |
1973年 | 155篇 |
1971年 | 157篇 |
Areas covered: This review covers the mechanism of action, safety and efficacy of sacituzumab govitecan in patients with previously treated, metastatic TNBC. Additionally, efficacy data in other epithelial malignancies is included based on a PubMed search for ‘sacituzumab govitecan’ and ‘clinical trial’.
Expert opinion: Sacituzumab govitecan has promising anti-cancer activity in patients with metastatic TNBC previously treated with at least two prior lines of systemic therapy based on a single arm Phase I/II clinical trial. A confirmatory Phase III randomized clinical trial is ongoing. Sacituzumab govitecan has a manageable side effect profile, with the most common adverse events being nausea, neutropenia, and diarrhea. The activity of sacituzumab govitecan likely extends beyond TNBC with promising early efficacy data in many other epithelial cancers, including hormone receptor-positive breast cancer. 相似文献
Areas covered: This article covers the pharmacokinetics and pharmacodynamics of vilazodone and provides an evaluation of the clinical usefulness of vilazodone for the treatment of MDD and anxiety disorders. A literature search was performed using PubMed/MEDLINE, Web of Science and the Cochrane Library.
Expert opinion: Studies have shown that vilazodone is significantly superior to placebo. However, vilazodone cannot as yet be recommended as a first-line treatment option for MDD as it is unclear whether the drug’s dual mechanism of action provides greater efficacy than prevailing treatment options. Moreover, more phase IV studies are needed to establish its efficacy and long-term safety in larger and more diverse populations. Although vilazodone may have an additional advantage for the treatment of anxiety symptoms in MDD, here also additional studies are required to confirm its efficacy over and above SSRI alternatives and other antidepressant treatments. Therefore, presently, vilazodone should be considered as a second- or third-line treatment option for MDD and GAD. 相似文献